Randomized trial · people
Thymosin alpha-1 lowered infections after colorectal cancer surgery
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In this trial, thymalfasin added to post-surgery chemotherapy was linked to fewer infections and complications in colorectal cancer patients, and the twice-weekly and three-times-weekly schedules gave similar infection results.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 400
- Published
- 2024
- Journal
- Biotechnol Genet Eng Rev
What they tested
The team tested whether thymalfasin injections, given with chemotherapy, improve immune function around surgery and long-term outcomes in people having colorectal cancer surgery.
How the study was done
A randomized controlled trial in 400 patients who had surgery to remove colorectal cancer at one hospital. Patients were randomly assigned to a chemotherapy regimen called XELOX alone or XELOX plus thymalfasin, and the thymalfasin patients were split into a conventional-dose group (n = 100, 1.6 mg twice a week) and a high-dose group (n = 100, 1.6 mg three times a week).

What they found
Both thymalfasin groups had significantly fewer infections around the time of surgery than the chemotherapy-only group, and the two dose groups did not differ from each other. The thymalfasin patients as a whole also had fewer early and late complications after surgery, less local recurrence (cancer returning at the original site) and less distant metastasis (spread to other organs). They also scored higher on immune function indexes around surgery and had a longer median disease-free survival, the time patients lived without the cancer coming back.
What it doesn’t show
This was a single-hospital trial, and the comparison group got chemotherapy alone rather than a dummy injection. The results apply to colorectal cancer patients on XELOX after surgery, not to other people or uses.
The paper
Niu et al. A Prospective and Randomized Control Study on Effects of Thymalfasin for Injection on Perioperative Immune Function and Long-term Prognosis of Patients with Colorectal Cancer. Biotechnol Genet Eng Rev. 2024.
The compound
More studies on Thymosin Alpha-1
- Thymosin Alpha-1 vs interferon in hepatitis B: better at follow-upMeta-analysis · people · 2008
- Thymosin Alpha-1 combo: 30.0% pCR before gastric cancer surgeryClinical trial · people · 2026
- Every study on Thymosin Alpha-1
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.